APA (7th ed.) Citation

Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., . . . Group, M. S. (2019). MSG-10: A Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. Journal of Antimicrobial Chemotherapy (JAC), 74(10), 3056. https://doi.org/10.1093/jac/dkz277

Chicago Style (17th ed.) Citation

Spec, Andrej, et al. "MSG-10: A Phase 2 Study of Oral Ibrexafungerp (SCY-078) Following Initial Echinocandin Therapy in Non-neutropenic Patients with Invasive Candidiasis." Journal of Antimicrobial Chemotherapy (JAC) 74, no. 10 (2019): 3056. https://doi.org/10.1093/jac/dkz277.

MLA (9th ed.) Citation

Spec, Andrej, et al. "MSG-10: A Phase 2 Study of Oral Ibrexafungerp (SCY-078) Following Initial Echinocandin Therapy in Non-neutropenic Patients with Invasive Candidiasis." Journal of Antimicrobial Chemotherapy (JAC), vol. 74, no. 10, 2019, p. 3056, https://doi.org/10.1093/jac/dkz277.